Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC)

Trial Profile

A phase 1/2 dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics and preliminary efficacy of DTX-SPL8783 (a docetaxel (DTX)-dendrimer conjugate) as monotherapy in patients with advanced solid tumours or in combination with nintedanib in patients with non-small cell lung cancer (NSCLC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Docetaxel (Primary) ; Nintedanib
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Starpharma
  • Most Recent Events

    • 08 Nov 2018 Planned number of patients changed from 45 to 65.
    • 23 May 2018 Planned number of patients changed from 16 to 45.
    • 25 Jan 2018 According to a Starpharma media release, University College London Hospital (UCLH) Cancer Clinical Trials Unit has been initiated for the phase 2 and is expected to commence recruitment shortly. Two further sites in the UK are also in the process of being initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top